COMMUNIQUÉS West-GlobeNewswire

Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045
03/06/2025
LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, today announced it [...]
Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes
03/06/2025
Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments BOSTON, MASSACHUSETTS, June 03, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a [...]
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
03/06/2025
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) , a clinical-stage [...]
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
03/06/2025
ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related [...]
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
03/06/2025
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Evaxion receives grant funding to design new polio vaccine
03/06/2025
Evaxion awarded a grant from the Gates Foundation Grant funds research aimed at ultimately eradicating polio, a highly infectious viral disease Evaxion will apply its leading AI-Immunology™ platform to identify and [...]
EssilorLuxottica: Résultat du paiement du dividende en actions et constatation de l’augmentation de capital correspondante
03/06/2025
Résultat du paiement du dividende en actions et constatation de l’augmentation de capital correspondante Paris, France (3 juin 2025 - 16h30) – L’Assemblée générale annuelle d’EssilorLuxottica a décidé de donner aux [...]
EssilorLuxottica: Result of the payment of dividends in shares and record of the corresponding capital increase
03/06/2025
Result of the payment of dividends in shares and record of the corresponding capital increase Paris, France (June 3, 2025 – 4:30 pm) – The Annual General Meeting of EssilorLuxottica has decided to grant to the [...]
Epilepsy Foundation of America Awards $250,000 at 13th Annual Shark Tank Competition
03/06/2025
Janine Erler, winner of the 2025 Investment Prize for Neumirna Therapeutics. Presenting the prize is Bernice Martin Lee, Epilepsy Foundation of America’s (EFA) Chief Executive Officer; Jacqueline French, MD, EFA’s [...]
Vital Wound Care Launches AI-Driven Wound App and Expands In-Home Services Across Greater Houston
03/06/2025
New AI-powered app and biologic wound therapies bring hospital-grade care to homes across Greater Houston. Image by Vital Wound Care HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- On May 1, Vital Wound Care introduced a [...]
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
03/06/2025
Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years CARTITUDE [...]
Johnson & Johnson’s AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
03/06/2025
Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms 1 Data show a nearly 50 percent reduction in disease progression in [...]
New analyses reinforce long-term benefit of DARZALEX® (daratumumab) subcutaneous-based quadruplet regimen for patients with newly diagnosed multiple myeloma
03/06/2025
Sustained MRD negativity (10 -5 ) rates at 24 months or longer were more than doubled in transplant eligible patients treated with daratumumab-VRd vs VRd alone in the Phase 3 PERSEUS study 1 Data from the Phase 3 [...]
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
03/06/2025
New long-term CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression-free at five years 1 CARTITUDE-4 analysis shows overall survival and progression-free benefits in standard and high- [...]
RESTEM to Present at the 2025 BIO International Convention
03/06/2025
MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Andres [...]
Conavi Medical Announces New Grant of Stock Options
03/06/2025
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“ Conavi Medical ” or the “ Company ”), announced that its board of directors (the “Board”) has approved grants of stock [...]
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
03/06/2025
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/2025
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired [...]
Vanqua Bio to Present at Upcoming Scientific Conferences
03/06/2025
CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio , a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its lead clinical program, VQ-101, at two upcoming [...]

Pages